Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Operations (2017 - 2025)

Cue Biopharma (CUE) has disclosed Cash from Operations for 9 consecutive years, with 1076000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 88.08% to 1076000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 21687000.0 through Dec 2025, up 40.3% year-over-year, with the annual reading at 21687000.0 for FY2025, 40.3% up from the prior year.
  • Cash from Operations hit 1076000.0 in Q4 2025 for Cue Biopharma, up from 9024000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1076000.0 in Q4 2025 to a low of 12848000.0 in Q2 2022.
  • Historically, Cash from Operations has averaged 8931008.3 across 5 years, with a median of 9777000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 52.09% in 2021 and later soared 88.08% in 2025.
  • Year by year, Cash from Operations stood at 10645166.0 in 2021, then grew by 1.23% to 10514000.0 in 2022, then fell by 4.22% to 10958000.0 in 2023, then grew by 17.61% to 9028000.0 in 2024, then surged by 88.08% to 1076000.0 in 2025.
  • Business Quant data shows Cash from Operations for CUE at 1076000.0 in Q4 2025, 9024000.0 in Q3 2025, and 3415000.0 in Q2 2025.